Day: August 6, 2024

SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc’s Palmitoylethanolamide (PEA) with Clearmind’s MEAI TEL AVIV, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that a new article published by Baraghithy et al. on the promising results from a recent study on 5-methoxy-2-aminoindane (“MEAI”), Clearmind Medicine Inc’s (Nasdaq: CMND) (“Clearmind” or “Clearmind Medicine”) innovative psychoactive molecule, for combating obesity. The study was meticulously conducted by a team of experts led by...

A Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced the renewal of its partnership with Canva, the world’s all-in-one visual communication platform. The multi-year renewal will continue to provide Canva’s customers with access to millions of Getty Images’ award-winning creative image and video assets. The renewal also expands the partnership to support Canva’s work to develop responsibly trained generative AI tools, as part of Canva’s $200 million Content Fund. Getty Images has partnered with Canva since 2018, adding to the Canva content library with millions of high-quality images and videos available to license. “We are pleased to extend and deepen...

Vancouver, Canada, Aug. 06, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that a new article published by Baraghithy et al, revealed promising results from a recent study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The study was meticulously conducted by a team of experts led by Prof. Joseph Tam, head of the Obesity and Metabolism Laboratory at the School of Pharmacy in the Hebrew University of Jerusalem. Key findings from the study include:Weight loss: MEAI significantly reduced diet-induced obesity in mice by decreasing fat mass while preserving lean mass. Improved Metabolism:...

201 Blocks Won in July, 27% Increase M/MBTC Production of 692 BTC, 17% Increase M/MIncreased BTC Holdings to 20,818 BTC; Total Cash and BTC of $1.6B as of July 31, 2024 Fort Lauderdale, FL, Aug. 06, 2024 (GLOBE NEWSWIRE) — MARA (NASDAQ: MARA) (“MARA” or the “Company”), one of the world’s largest publicly traded bitcoin (“BTC”) miners and a leader in supporting and securing the Bitcoin ecosystem, today published unaudited BTC production and miner installation updates for July 2024. Management Commentary“Our hash rate recovery effort at the Ellendale facility where we are hosted by Applied Digital is complete, and block wins in July increased 27% over the prior month,” said Fred Thiel, MARA’s chairman and CEO. “BTC production last month rose 17% to 692 BTC compared...

Patient enrollment has accelerated, now with 13 patients enrolled in trial TFF TAC at ~20% of the oral tacrolimus dose prevented acute rejection and achieved >80% of the previous oral trough blood levels — leading to diminished drug burden 9 out of 9 (100%) patients who completed the 12-week treatment chose to remain on TFF TAC by proceeding to the long-term extension Phase; 2 patients have been treated for over a year and 6 patients have been treated for more than 6 months Observed a 6.5-fold reduction in the number of abnormally expressed rejection-related gene sets after treatment with TFF TAC No production of donor-specific antibodies (DSA) after treatment with TFF TAC FORT WORTH, Texas, Aug. 06, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company...

ST. GALLEN, Switzerland, Aug. 06, 2024 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global sports technology company focused on creating immersive experiences for sports fans and bettors, today announced that Craig Felenstein, the Company’s Chief Financial Officer, will participate in Canaccord Genuity’s 44th Annual Growth Conference on Wednesday August 14, 2024. The fireside chat will take place at 1:30 pm eastern time and will be webcast live at investors.sportradar.com. About SportradarSportradar Group AG (NASDAQ: SRAD), founded in 2001, is a leading global sports technology company creating immersive experiences for sports fans and bettors. Positioned at the intersection of the sports, media and betting industries, the company provides sports federations, news media, consumer...